By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CytRx Corporation 

11726 San Vicente Boulevard
Suite 650
Los Angeles  California  90049  U.S.A.
Phone: 310-826-5648 Fax: 310-826-6139


Company News
CytRx (CYTR) Announces FDA Agreement On Regulatory Pathway To Approval For Aldoxorubicin In Soft Tissue Sarcomas 4/19/2017 6:25:01 AM
CytRx (CYTR) Reports 2016 Financial Results 3/16/2017 11:52:27 AM
CytRx (CYTR) Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas 1/4/2017 8:04:33 AM
CytRx (CYTR) Appoints Chief Medical Officer Dr. Daniel Levitt As Chief Operating Officer 12/19/2016 10:51:38 AM
CytRx (CYTR) Announces $8.1 Million Registered Direct Offering Of Common Stock 12/13/2016 7:19:30 AM
Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx (CYTR) Board Of Directors 12/2/2016 8:26:00 AM
CytRx (CYTR) Plans to File NDA for Once-Failed Sarcoma Drug While Columnist Raises Questions Over Efficacy and CEO Salary Amid Struggle 11/30/2016 5:55:30 AM
CytRx (CYTR) Reports Statistically Significant Updated Results From Pivotal Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcomas 11/29/2016 6:32:47 AM
CytRx (CYTR) Presents Positive Interim Results From On-Going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting 11/14/2016 6:29:03 AM
CytRx (CYTR) Reports Third Quarter 2016 Financial Results 11/10/2016 4:19:57 PM